U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus to Present at KeyBanc Capital Markets Virtual Investor Forum
Simulations Plus and the University of Bath Awarded New FDA Grant
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
Simulations Plus Launches Corporate Development Initiative
Simulations Plus to Participate in Upcoming Healthcare Conferences
Simulations Plus Embarks on Collaboration with Northeastern University
Simulations Plus Announces Leadership Appointments